IRMD
NEUTRAL
$93.4
Live
IRADIMED CORPORATION · NASDAQ
Target $118.67
(+27.1%)
$50.0
52W Range
$107.9
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$1.19B
P/E
53.37
ROE
24.8%
Profit margin
26.8%
Debt/Equity
N/A
Dividend yield
0.86%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
IRMD presents a dichotomy between exceptional operational performance and extreme valuation premiums. While the Piotroski F-Score of 4/9 indicates stable financial health and the company boasts an impressive 76.75% gross margin and a consistent 25-quarter earnings beat record, the stock is trading significantly above its Graham Number ($17.07) and Intrinsic Value ($51.62). The strong fundamental growth is currently offset by bearish insider activity from the CEO and a completely bearish technical trend (0/100).
Key Strengths
Exceptional profitability with 76.75% gross margins and 26.82% profit margins
Strong return on equity (ROE) of 24.78%
Outstanding liquidity position with a current ratio of 7.98
Consistent earnings track record with 3/4 recent beats and a long history of surprises
Steady double-digit growth in both revenue (17%) and earnings (24.8%)
Key Risks
Severe valuation stretch with a P/E of 53.37 and P/S of 14.24
Bearish insider sentiment with the CEO selling $9.44M in shares
Technical trend is currently 0/100, indicating strong bearish momentum
Significant gap between current price ($93.40) and defensive fair value ($17.07)
Low dividend yield (0.86%) provides little downside protection
AI Fair Value Estimate
Based on comprehensive analysis
$62.5
-33.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
63
Strong
20
85
95
70
45
AI Verdict
Operationally elite but fundamentally overpriced
Key drivers: High margins, Earnings consistency, Valuation premium, Insider selling
Confidence
90%
Value
20/100
Ref P/E 53.37, Graham Number $17.07
Positives
- P/E is lower than the sector average of 89.71
Watchpoints
- Price is 5.4x the Graham Number
- Price is 80% above growth-based intrinsic value
- High Price/Book (12.62)
Future
85/100
Ref Growth rates and Analyst Targets
Positives
- Strong YoY earnings growth (24.8%)
- Positive analyst target price of $118.67
- Consistent quarterly EPS progression
Watchpoints
- Technical trend is currently bearish
Past
95/100
Ref Historical trends and Earnings track record
Positives
- 5-year price change of +324.4%
- Consistent earnings beats over 25 quarters
- Strong historical revenue growth
Watchpoints
No urgent risks highlighted.
Health
70/100
Ref Piotroski F-Score 4/9, Current Ratio 7.98
Positives
- Very high current ratio (7.98)
- Strong ROA (15.78%)
Watchpoints
- Piotroski F-Score is only 4/9 (Stable, not Strong)
Dividend
45/100
Ref Yield 0.86%, Payout 38.86%
Positives
- Sustainable payout ratio (38.86%)
Watchpoints
- Very low yield (0.86%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$93.4
Analyst Target
$118.67
Upside/Downside
+27.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IRMD and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IRMD
IRADIMED CORPORATION
Primary
|
+324.4% | +136.8% | +89.2% | +31.5% | -7.3% | -2.9% |
|
BLFS
BioLife Solutions, Inc.
Peer
|
-40.8% | -0.5% | -10.7% | +10.1% | -2.1% | +1.8% |
|
ALVO
Alvotech
Peer
|
-65.9% | -71.8% | -66.2% | -52.0% | -17.7% | -1.6% |
|
EYPT
EyePoint, Inc.
Peer
|
+41.6% | +326.8% | +243.1% | +2.1% | -9.6% | +8.8% |
|
BFLY
Butterfly Network, Inc.
Peer
|
-76.9% | +59.4% | +8.9% | +128.9% | +14.2% | +8.4% |
IRM
IRADIMED CORPORATION
Primary
5Y
+324.4%
3Y
+136.8%
1Y
+89.2%
6M
+31.5%
1M
-7.3%
1W
-2.9%
BLF
BioLife Solutions, Inc.
Peer
5Y
-40.8%
3Y
-0.5%
1Y
-10.7%
6M
+10.1%
1M
-2.1%
1W
+1.8%
ALV
Alvotech
Peer
5Y
-65.9%
3Y
-71.8%
1Y
-66.2%
6M
-52.0%
1M
-17.7%
1W
-1.6%
EYP
EyePoint, Inc.
Peer
5Y
+41.6%
3Y
+326.8%
1Y
+243.1%
6M
+2.1%
1M
-9.6%
1W
+8.8%
BFL
Butterfly Network, Inc.
Peer
5Y
-76.9%
3Y
+59.4%
1Y
+8.9%
6M
+128.9%
1M
+14.2%
1W
+8.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
53.37
Forward P/E
40.26
PEG Ratio
N/A
P/B Ratio
12.62
P/S Ratio
14.24
EV/Revenue
13.63
EV/EBITDA
41.84
Market Cap
$1.19B
Profitability
Profit margins and return metrics
Profit Margin
26.82%
Operating Margin
31.26%
Gross Margin
76.75%
ROE
24.78%
ROA
15.78%
Growth
Revenue and earnings growth rates
Revenue Growth
+17.0%
Earnings Growth
+24.8%
Q/Q Revenue Growth
+17.03%
Q/Q Earnings Growth
+25.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
7.98
Strong
Quick Ratio
6.37
Excellent
Cash/Share
$4.0
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
75.1%
Op. Margin
31.3%
Net Margin
28.4%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.1B
Debt/Equity
0.15x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
93%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-10
$0.5
+14.9% surprise
2025-11-03
$0.47
+3.3% surprise
2025-08-01
$0.49
+12.6% surprise
Healthcare Sector Comparison
Comparing IRMD against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
P/E Ratio
53.37
This Stock
vs
88.64
Sector Avg
-39.8%
(Discount)
Return on Equity (ROE)
24.78%
This Stock
vs
-46.09%
Sector Avg
-153.8%
(Below Avg)
Profit Margin
26.82%
This Stock
vs
-19.58%
Sector Avg
-237.0%
(Weaker)
Revenue Growth
17.0%
This Stock
vs
88.16%
Sector Avg
-80.7%
(Slower)
Current Ratio
7.98
This Stock
vs
3.58
Sector Avg
+122.9%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IRMD
IRADIMED CORPORATION
|
NEUTRAL | $1.19B | 53.37 | 24.8% | 26.8% | $93.4 | |
|
BLFS
BioLife Solutions, Inc.
|
NEUTRAL | $1.2B | - | -5.2% | -3.2% | $24.87 | Compare |
|
ALVO
Alvotech
|
BEARISH | $1.19B | 16.61 | -% | 12.1% | $3.82 | Compare |
|
EYPT
EyePoint, Inc.
|
NEUTRAL | $1.18B | - | -72.2% | -% | $14.17 | Compare |
|
BFLY
Butterfly Network, Inc.
|
NEUTRAL | $1.14B | - | -41.4% | -90.3% | $4.51 | Compare |
IRMD
IRADIMED CORPORATION
NEUTRAL
Mkt Cap
$1.2B
P/E
53.4
ROE
24.8%
Price
$93.4
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | SUSI ROGER E | Chief Executive Officer | Sale | 7,500 | $717,208 |
| 2026-03-30 | SUSI ROGER E | Chief Executive Officer | Sale | 7,500 | $712,614 |
| 2026-03-24 | SUSI ROGER E | Chief Executive Officer | Sale | 7,500 | $752,609 |
| 2026-03-17 | SUSI ROGER E | Chief Executive Officer | Sale | 7,500 | $762,970 |
| 2026-03-10 | SUSI ROGER E | Chief Executive Officer | Sale | 7,500 | $750,475 |
| 2026-03-06 | SUSI ROGER E | Chief Executive Officer | Sale | 7,500 | $737,919 |
| 2026-02-13 | ALLEN MONTY K | Director | Sale | 1,000 | $100,256 |
| 2026-01-26 | SUSI ROGER E | Chief Executive Officer | Sale | 5,000 | $503,255 |
| 2026-01-20 | SUSI ROGER E | Chief Executive Officer | Sale | 5,000 | $509,225 |
| 2026-01-12 | SUSI ROGER E | Chief Executive Officer | Sale | 5,000 | $487,231 |
| 2026-01-05 | SUSI ROGER E | Chief Executive Officer | Sale | 5,000 | $488,417 |
| 2025-12-29 | SUSI ROGER E | Chief Executive Officer | Sale | 5,000 | $488,317 |
| 2025-12-22 | SUSI ROGER E | Chief Executive Officer | Sale | 5,000 | $483,672 |
| 2025-12-15 | SUSI ROGER E | Chief Executive Officer | Sale | 5,000 | $483,729 |
| 2025-12-11 | GLENN JOHN F | Chief Financial Officer | Sale | 15,000 | $1,459,342 |
SUSI ROGER E
Chief Executive Officer
2026-04-07
7,500 shares
·
$717,208
SUSI ROGER E
Chief Executive Officer
2026-03-30
7,500 shares
·
$712,614
SUSI ROGER E
Chief Executive Officer
2026-03-24
7,500 shares
·
$752,609
SUSI ROGER E
Chief Executive Officer
2026-03-17
7,500 shares
·
$762,970
SUSI ROGER E
Chief Executive Officer
2026-03-10
7,500 shares
·
$750,475
SUSI ROGER E
Chief Executive Officer
2026-03-06
7,500 shares
·
$737,919
ALLEN MONTY K
Director
2026-02-13
1,000 shares
·
$100,256
SUSI ROGER E
Chief Executive Officer
2026-01-26
5,000 shares
·
$503,255
SUSI ROGER E
Chief Executive Officer
2026-01-20
5,000 shares
·
$509,225
SUSI ROGER E
Chief Executive Officer
2026-01-12
5,000 shares
·
$487,231
SUSI ROGER E
Chief Executive Officer
2026-01-05
5,000 shares
·
$488,417
SUSI ROGER E
Chief Executive Officer
2025-12-29
5,000 shares
·
$488,317
SUSI ROGER E
Chief Executive Officer
2025-12-22
5,000 shares
·
$483,672
SUSI ROGER E
Chief Executive Officer
2025-12-15
5,000 shares
·
$483,729
GLENN JOHN F
Chief Financial Officer
2025-12-11
15,000 shares
·
$1,459,342
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
3 analysts
Freedom Broker
2026-04-02
Buy
Past News Coverage
Recent headlines mentioning IRMD from our newsroom.
Newest → oldest
No matching news yet.